BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 24061041)

  • 1. Targeted therapies: another option for metastatic RCC.
    Hutchinson L
    Nat Rev Clin Oncol; 2013 Nov; 10(11):607. PubMed ID: 24061041
    [No Abstract]   [Full Text] [Related]  

  • 2. Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma.
    Procopio G; Verzoni E; de Braud F
    Oncology; 2013; 84(1):39-42. PubMed ID: 23076302
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-clear cell renal cell carcinoma, part 2: therapy.
    Valenca LB; Hirsch MS; Choueiri TK; Harshman LC
    Clin Adv Hematol Oncol; 2015 Jun; 13(6):383-91. PubMed ID: 26352894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies in metastatic renal cell carcinoma: overview of the past year.
    Gross-Goupil M; Massard C; Ravaud A
    Curr Urol Rep; 2012 Feb; 13(1):16-23. PubMed ID: 22139625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.
    Ye D; Eto M; Chung JS; Kimura G; Chang WC; Chang YH; Pang ST; Lee JL; Niu Y; Gurney H; Uemura H
    Clin Genitourin Cancer; 2014 Aug; 12(4):225-33. PubMed ID: 24630778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
    Raspollini MR
    Curr Oncol Rep; 2007 Sep; 9(5):331. PubMed ID: 17706159
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel challenges associated with novel agents: the evolving scenario in renal cell carcinoma.
    Di Lorenzo G; Buonerba C
    Future Oncol; 2016 Feb; 12(3):277-9. PubMed ID: 26768297
    [No Abstract]   [Full Text] [Related]  

  • 8. Current and Emerging Treatments for Metastatic Renal Cell Carcinoma.
    Cavaliere C; D'Aniello C; Pepa CD; Pisconti S; Berretta M; Facchini G
    Curr Cancer Drug Targets; 2018; 18(5):468-479. PubMed ID: 28183256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Biomarkers for Molecularly Targeted Therapies in Renal Cell Carcinoma.
    Brugarolas J
    J Natl Compr Canc Netw; 2016 Jul; 14(7):925-7. PubMed ID: 27407131
    [No Abstract]   [Full Text] [Related]  

  • 10. Immune Checkpoint Therapy in Renal Cell Carcinoma.
    Lee CH; Motzer RJ
    Cancer J; 2016; 22(2):92-5. PubMed ID: 27111903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy for metastatic RCC--questions remain.
    Breau RH; Leibovich BC
    Nat Rev Urol; 2009 Nov; 6(11):580-1. PubMed ID: 19890336
    [No Abstract]   [Full Text] [Related]  

  • 12. Optimizing treatment for metastatic renal cell carcinoma.
    Patard JJ; Porta C; Wagstaff J; Gschwend JE
    Expert Rev Anticancer Ther; 2011 Dec; 11(12):1901-11. PubMed ID: 22117157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and Emerging Therapeutic Targets for Metastatic Renal Cell Carcinoma.
    Zarrabi K; Wu S
    Curr Oncol Rep; 2018 Apr; 20(5):41. PubMed ID: 29611002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effectiveness of Sorafenib over Other Targeted Agents in the Second-Line Treatment of Metastatic Renal Cell Carcinoma: a Meta-Analysis.
    Huang HF; Fan XR; Ji ZG
    Pathol Oncol Res; 2019 Oct; 25(4):1497-1503. PubMed ID: 30421088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?
    Santoni M; Rizzo M; Burattini L; Berardi R; Carteni G; Cascinu S
    Curr Cancer Drug Targets; 2013 Mar; 13(3):313-25. PubMed ID: 23190497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New perspectives in the treatment of metastatic renal cell carcinoma.
    Barrière J; Hoch B; Ferrero JM
    Crit Rev Oncol Hematol; 2012 Dec; 84 Suppl 1():e16-23. PubMed ID: 22099727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
    Hutson TE; Quinn DI
    Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
    Mizutani Y
    Int J Urol; 2009 May; 16(5):444-8. PubMed ID: 19298634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic therapy in renal cell carcinoma: advancing paradigms.
    Posadas EM; Figlin RA
    Oncology (Williston Park); 2012 Mar; 26(3):290-301. PubMed ID: 22545314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
    Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
    Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.